Intervention not reported
Total number of adverse events (withdrawals due to lack of effect)c · patients with varus medial osteoarthritis of the knee
The intervention showed no clear difference in total number of adverse events (withdrawals due to lack of effect)c (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · psoriatic arthritis
Methotrexate showed no clear difference in withdrawals due to adverse events (WAEs) assessed by number of events compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Number of participant withdrawals due to adverse events ‐ not measured · patients with acute gout
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · Paget's disease of bone
It is very uncertain whether zoledronate changes number of participants who withdrew due to adverse events… compared with pamidronate or risedronate (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · women with PMS
1 finding from 1 review
Intervention not reported
Severe adverse events or withdrawals (due to adverse events) ‐ not reported · People with hip or knee osteoarthritis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Withdrawals due to adverse events · psoriatic arthritis
2 findings from 1 review
Number of participant withdrawals due to adverse events or treatment intolerance · rotator cuff disease
Shock wave therapy showed no clear difference in number of participant withdrawals due to adverse events or treatment… compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) leads to higher withdrawals due to adverse events All doses of certolizumab pegol… compared with placebo (with or without MTX) (high certainty).
1 finding from 1 review
Adverse events (participants with adverse events or withdrawals due to adverse events) · Adults (any age/sex) with chronic periodontitis (>=5 teeth remaining; PPD >4 mm), with or without hypertension
1 finding from 1 review
Adverse events (participants with adverse events or withdrawals due to adverse events) · Adults (any age/sex) with chronic periodontitis (>=5 teeth remaining; PPD >4 mm), with or without hypertension
1 finding from 1 review
SoF 1 (Adverse effects): Only 1 study reported that 1 participant in the treatment group experienced a myocardial infarction during the study period. 1 study reported no adverse effects. The remaining 2 studies did not…
2 studies · 294 participants
Low
Adverse events Adverse events includes withdrawal and drop‐outs that could be clearly identified as due to an adverse event · patients with fibromyalgia
Acupuncture showed no clear difference in adverse events Adverse events includes withdrawal and drop‐outs that… compared with placebo or sham acupuncture (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Raynaud's phenomenon
Calcium channel blockers showed no clear difference in number of withdrawals due to adverse events Number of participants… compared with placebo (low certainty).
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to non‐serious adverse events Measured by: proportion of participants withdrawn from treatment Average study duration (range): 5.60 months (0.6 months to 41 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to adverse events of unknown severity Measured by: proportion of participants withdrawn from treatment Average study duration (range): 4.6 months (21 days to 36 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review
Intervention not reported
Withdrawal of methylphenidate due to serious adverse events (non‐comparative cohort studies) Measured by: proportion of participants withdrawn from treatment Average study duration (range): 7.9 months (1 month to 37 months) · children and adolescents aged 18 years and under diagnosed with ADHD
1 finding from 1 review